Early signs of recovery amongst small businesses in Q1, 2025 – ASSOCHAM Dun & Bradstreet Small Business Confidence Index
MUMBAI, India, March 11, 2025 /PRNewswire/ -- ASSOCHAM along with Dun &…
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Significantly more patients treated with Sotyktu achieved ACR and PASI response rates…
Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
At three years of EYLEA HD treatment, the vast majority of patients…
Aqua Pennsylvania Acquires Greenville Sanitary Authority Wastewater System in Mercer County
Acquisition reflects company’s commitment to providing reliable wastewater treatment and environmental protectionBRYN…
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Application based on TROPION-Lung05 phase 2 trial and supported by data from…
Frost & Sullivan Recognizes AllianceOne and Central Florida Expressway Authority with 2024 Customer Value Leadership Award
Award Highlights AllianceOne and the Central Florida Expressway Authority's strong partnership through cultural…
GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz
** IND submitted to the FDA showing significantly improved patient condition when…
Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc. – OS…
Lingokids Demonstrates Effective Child Learning in Just 8 Weeks: Results from an Efficacy Study
Improvements of 6% in literacy, 7% in math, and 10% in socio-emotional…
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FASTs 17th Annual Global Science Summit
November 09, 2024 10:30 ET | Source: Ultragenyx Pharmaceutical Inc. Phase 1/2…